Cameroon has been challenged to display its sero-prevalence rate. This requirement comes on the heels of the effective conduct of mass vaccination campaign against ‘’peste des petits ruminants’’ in 2019. Surveys were conducted with a view of ensuring the quality of the work carried out in the field. The objective was to evaluate the level of protection of animals that were vaccinated against this disease. MINEPIA personnel, in close collaboration with the National Veterinary Laboratory, LANAVET, were sent to the field in the 10 regions. They collected blood samples from sheep and goats.
Some zootechnical and veterinary centres, 155 in all, and small ruminant breeders, 465 on that occasion, underwent some random drawing. 10 sheep and/or goats were also drawn at random in the various herds, be they vaccinated or not. The animals concerned, as requirement, had to be 3 months old and above. Their samples were thus collected for the purpose of laboratory analyses.
News beaming from various regions are optimistics. A training session aimed at ungrading the skills of field surveyors preceded their departure for various venues across the country. LANAVET executives, led by the new Director General, Dr Abel WADE, were the facilitators. This presence, both symbolic and significant, has rather come to open a new collaborative era.
The Minister of Livestock, Fisheries and Animal Industries, Dr Taïga, brought all his full weight to bear the national launch in Nanga-Éboko on the 25th of September, 2019. The said campaign did mobilize at least 1,500 personnel from MINEPIA decentralized services. They were divided up into teams of vaccinators. They did criss-crossed 12,668 villages within the country to vaccinate 4,731,522 sheep and goats against 6,000,000. The on-going insecurity explains this slight difference in the Far North, South West and North West regions. Over one million livestock farming households took advantage of this operation. Women and young people (under 35) also participated with a rate estimated at 14% and 15% respectively. Only the sero-prevalence rate is still expected.